X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TRV027 is a novel AT1 receptor selective agonist that specifically binds to and rebalances AT1 receptor activation within the RAAS, blocking the damaging pathway that leads to acute lung damage and abnormal blood clotting.
Lead Product(s): TRV027
Therapeutic Area: Infections and Infectious Diseases Product Name: TRV027
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
TRV027, the Company’s novel AT1 receptor selective agonist, represents a new approach to targeting the AT1 receptor and reversing organ damage caused by RAAS imbalance, has been selected for an NIH ACTIV trial in COVID-19 patients.
Lead Product(s): TRV027
Therapeutic Area: Infections and Infectious Diseases Product Name: TRV027
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting.
Lead Product(s): TRV027
Therapeutic Area: Infections and Infectious Diseases Product Name: TRV027
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19.
Lead Product(s): TRV027
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TRV027
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Imperial College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
A molecule known as TRV027, could put a brake on many of the dangerous processes which occur in Covid-19, such as lung damage and blood clots. The cell pathways targeted by the drug are thought to be major drivers of severe illness in Covid-19.
Lead Product(s): TRV027
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Imperial College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Lead Product(s): TRV027
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Trevena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
